Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RX-3117 (fluorocyclopentenylcytosine) 是一种新型的胞苷类似物,在几种癌细胞系中显示出抗癌活性,包括对吉西他滨耐药的变体。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,330 | 现货 | ||
2 mg | ¥ 1,890 | 现货 | ||
5 mg | ¥ 2,890 | 现货 | ||
10 mg | ¥ 4,160 | 现货 | ||
25 mg | ¥ 6,520 | 现货 | ||
50 mg | ¥ 8,790 | 现货 | ||
100 mg | ¥ 11,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,180 | 现货 |
产品描述 | RX-3117 (fluorocyclopentenylcytosine) is a novel a cytidine analog. RX-3117 displays anticancer activity in several cancer cell lines, including gemcitabine-resistant variants. |
体外活性 | RX-3117 was a very poor substrate for cytidine deaminase (66,000-fold less than gemcitabine). RX-3117 showed a different sensitivity profile compared to cyclopentenyl-cytosine and azacytidine, substrates for uridine-cytidine-kinase. Insensitive U937 cells 1 μM RX-3117 resulted in 90% inhibition of RNA synthesis but 100 μM RX-3117 was required in A2780 and CCRF-CEM cells. RX-3117 at IC50 values did not affect the integrity of RNA [1]. |
体内活性 | RX-3117 (p.o.) was examined in 9 different human tumor xenograft models grown subcutaneously in athymic nude mice. In the Colo 205, H460, H69 and CaSki models, gemcitabine treatment resulted in 28%, 30%, 25% and 0% tumor growth inhibition (TGI), respectively. Whereas oral treatment with RX-3117 induced 100%, 78%, 62% and 66% TGI, respectively [2]. |
别名 | fluorocyclopentenylcytosine, TV-1360 |
分子量 | 257.22 |
分子式 | C10H12FN3O4 |
CAS No. | 865838-26-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (194.39 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.8877 mL | 19.4386 mL | 38.8772 mL | 97.1931 mL |
5 mM | 0.7775 mL | 3.8877 mL | 7.7754 mL | 19.4386 mL | |
10 mM | 0.3888 mL | 1.9439 mL | 3.8877 mL | 9.7193 mL | |
20 mM | 0.1944 mL | 0.9719 mL | 1.9439 mL | 4.8597 mL | |
50 mM | 0.0778 mL | 0.3888 mL | 0.7775 mL | 1.9439 mL | |
100 mM | 0.0389 mL | 0.1944 mL | 0.3888 mL | 0.9719 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
RX-3117 865838-26-2 Cell Cycle/Checkpoint DNA Damage/DNA Repair Nucleoside Antimetabolite/Analog fluorocyclopentenylcytosine S phase DNMT1 TV-1360 inhibit orally active RX 3117 apoptosis RX3117 antiproliferative TV 1360 Inhibitor TV1360 anti-tumour inhibitor